Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia

• Status: Active, not recruiting
• Trial end date: 2026-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment. In our pre-clinical study, we found that targeting histone deacetylase inhibitor 3 (HDAC3)degraded PML-RARa oncoprotein and induced differentiation and apoptosis of RA and As resistant APL in vitro and in vivo. In this study, we evaluate the efficacy and feasibility of combination therapy for HDAC3 inhibitor and venetoclax in patients with refractory APL.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Collaborator: Shanghai Clinical Research Center
• Treatments: Venetoclax

Criteria

Inclusion Criteria:

• Patients with PML-RARα+ APL

• Patients in non-remission status after treatment of RA combined with As

• Patients with life expectance >=3 months

• Inform consent provided

Exclusion Criteria:

• Patients with incontrollable infection

• Patients with life-expectancy less than 2 months

• Patients with abnormal liver (>3XN) and renal function (>3XN）